ReGen Biologics Inc (fka RGBOQ)

[SPIN]

ReGen Biologics To Exhibit at 2007 AOSSM Annual Meeting
Monday July 9, 4:05 pm ET

FRANKLIN LAKES, N.J.--(BUSINESS WIRE)--ReGen Biologics (OTCBB: RGBI - News) will attend the annual meeting of the American Orthopaedic Society for Sports Medicine (AOSSM), being held this week in Calgary, Canada. The company will exhibit the CMI(TM) collagen meniscus implant, which is CE marked and cleared for sale in Europe for both medial and lateral use.

"We look forward to meeting with sports medicine specialists from around the world at this meeting," commented Gerald E. Bisbee, Jr., Ph.D., Chairman and Chief Executive Officer of ReGen Biologics. "It provides an excellent opportunity for us to share data and information about our products, and demonstrate how we can work together with surgeons to improve patient outcomes."

The American Orthopaedic Society for Sports Medicine (AOSSM) is a national organization of orthopaedic surgeons specializing in sports medicine, including national and international sports medicine leaders. The AOSSM works closely with many other sports medicine specialists and clinicians, including family physicians, emergency physicians, pediatricians, athletic trainers and physical therapists, to improve the identification, prevention, treatment and rehabilitation of sports injuries.

Formed in 1972 primarily as a forum for education and research, the AOSSM has increased from its modest initial membership of fewer than 100 to close to 2,000. For information on the society, the annual meeting, or scheduled presentations visit www.aossm.org.

About ReGen Biologics, Inc.:

ReGen Biologics is an orthopedic products company that develops, manufactures and markets innovative tissue growth and repair products for U.S. and global markets. ReGen's patented collagen scaffold technology includes applications in orthopedics, general surgery, spine, cardiovascular and drug delivery. ReGen's first approved product using its collagen scaffold technology is the CMI(TM), a meniscus application, which is cleared for sale in Europe and marketed through ReGen's European subsidiary, ReGen Biologics AG. ReGen has submitted a 510(k) to the FDA in the U.S. for clearance of the CMI.

ReGen has conducted the largest human clinical trial on an arthroscopic meniscus procedure. The resulting database has unique value in better understanding meniscus injuries. The company is headquartered in Franklin Lakes, NJ and manufactures its collagen scaffold products in its ISO Certified facility located in Redwood City, CA. For more information on ReGen, visit http://www.regenbio.com.

This press release contains forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on the current expectations and beliefs of the management of ReGen and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including those discussed in the Risk Factors section of ReGen's 2006 annual report on Form 10-K and additional filings with the SEC. ReGen's filings with the SEC are available to the public at the Company's website at http://www.regenbio.com, from commercial document-retrieval services and at the Web site maintained by the SEC at http://www.sec.gov.

Contact:

ReGen Biologics, Inc.
Brion Umidi, 201-651-3515
Chief Financial Officer
[e-mail]
or
Cameron Associates
Al Palombo, 212-245-8800 Ext. 209
Investor Relations
[e-mail]

Source: ReGen Biologics, Inc.